Lv1
38 积分 2023-01-26 加入
Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial
4天前
已完结
Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy
1个月前
已完结
BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy
4个月前
已完结
Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models
6个月前
已关闭
Anti-angiogenesis enhances the tumor immunotherapeutical effect of recombinant CD80 fusion protein
7个月前
已完结
Daratumumab in Relapsed or Refractory Pediatric Immune Thrombocytopenia
10个月前
已完结
Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial
10个月前
已完结
To platform or not to platform: Strategic considerations for antibody formulation in early clinical development
10个月前
已完结
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
11个月前
已完结
Recent progress in ITP treatment
11个月前
已完结
皖公网安备34019202002308
